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The discovery of innate lymphoid cells (ILC) has profoundly influenced the understanding
of innate and adaptive immune crosstalk in health and disease. ILC and T cells
share developmental and functional characteristics such as the lineage-specifying
transcription factors and effector cytokines, but importantly ILC do not display rearranged
antigen-specific receptors. Similar to T cells ILC are subdivided into 3 different helper-
like subtypes, namely ILC1-3, and a killer-like subtype comprising natural killer (NK) cells.
Increasing evidence supports the physiological relevance of ILC, e.g., in wound healing
and defense against parasites, as well as their pathogenic role in allergy, inflammatory
bowel diseases or psoriasis. Group 2 ILC have been attributed to the pathogenesis of
allergic diseases like asthma and atopic dermatitis. Other inflammatory skin diseases
such as allergic contact dermatitis are profoundly shaped by inflammatory NK cells.
This article reviews the role of ILC in allergic skin diseases with a major focus on ILC2.
While group 2 ILC are suggested to contribute to the pathogenesis of type 2 dominated
inflammation as seen in atopic dermatitis, we have shown that lack of ILC2 in type
1 dominated contact hypersensitivity results in enhanced inflammation, suggesting a
regulatory role of ILC2 in this context. We provide a concept of how ILC2 may influence
context dependent the mutual counterbalance between type I and type II immune
responses in allergic skin diseases.
Keywords: innate lymphoid cells, allergic contact dermatitis, atopic dermatitis, counter regulation, immune
crosstalk
INTRODUCTION
Innate lymphoid cells (ILC) are innate immune cells of the lymphoid lineage, which have a similar
functional diversity as T cell subsets based on the developmental dependency on lineage-specifying
transcription factors and effector functions. Like T and B lymphocytes, all ILC derive from a
hematopoietic stem cell-derived common lymphoid precursor (CLP) cell in the bone marrow
(Figure 1). The CLP gives rise to an early innate lymphoid precursor (EILP) that expresses the
transcription factor (TF) T-cell factor 1 (Tcf-1). From this branching point natural killer (NK)
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cells develop via a NK precursor (NKp) and by upregulating
the TFs eomesodermin (EOMES) and T-box transcription factor
TBX21 (T-bet). The other branch develops into an Id2 expressing
common helper-like ILC progenitor (CHILP). C-C chemokine
receptor type 6 positive (CCR6+) ILC3 can directly evolve form
the CHILP depending on the expression of RAR-related orphan
receptor (ROR)γt. All the remaining helper-like ILC subtypes,
namely ILC1, ILC2, and ILC3, evolve from an innate lymphoid
cell precursor (ILCP) which expresses the TF promyelocytic
leukemia zinc finger (PLZF). CCR6− ILC3 can adapt a more
ILC1-like phenotype by downregulating RORγt and upregulating
T-bet. These cells are called ex ILC3. Production of their marker
cytokines attributes certain physiological and pathological roles
to the particular ILC subtype (Figure 1). Effector ILC can be
classified into three interleukin-7 receptor positive (IL-7R+)
helper-like ILC groups (ILC1-3) and one IL-7R− cytotoxic ILC
group (NK cells) (1–3). More recently, several groups have also
identified IL-10 secreting ILCwith proposed regulatory functions
(4–6). Helper-like ILC and NK cells are mainly populated at
FIGURE 1 | Graphical summary of innate lymphoid cell (ILC) subtypes. ILC as well as T and B lymphocytes (T/B) derive from a common lymphoid precursor (CLP).
The CLP gives rise to an early innate lymphoid precursor (EILP) that expresses the transcription factor (TF) T-cell factor 1 (Tcf-1). From this point natural killer (NK) cells
develop via a NK precursor (NKp) and upregulate the TFs eomesodermin (EOMES) and T-box transcription factor TBX21 (T-bet). The helper-like ILC lineage derives
from an Id2 expressing common helper-like ILC progenitor (CHILP) from which C-C chemokine receptor type 6 positive (CCR6+) ILC3 can directly evolve depending
on the expression of RAR-related orphan receptor (ROR)γt. All the remaining helper-like ILC subtypes, namely ILC1, ILC2, and ILC3, evolve from an innate lymphoid
cell precursor (ILCP) which expresses the TF promyelocytic leukemia zinc finger (PLZF). CCR6− ILC3 can adapt a more ILC1-like phenotype by downregulating
RORγt and upregulating T-bet. These cells are called ex ILC3. Production of their marker cytokines attributes certain physiological and pathological roles to the
particular ILC subtype. IBD, inflammatory bowel disease; ACD, allergic contact dermatitis; AD, atopic dermatitis.
barrier surfaces like the skin, gut, and the respiratory tract,
although significant numbers can be detected in secondary
and tertiary lymphoid organs in homeostasis and disease (7).
Besides the bone-marrow, alternative sites of development exist,
such as secondary lymphoid organs or even non-hematopoietic
organs such as the gut (8–10). While ILC development continues
throughout life, it is known that some ILC lineages are long-
lived, and seed their designated tissues early in embryogenesis as
demonstrated by parabiosis experiments in mice that show only
little replenishment of helper-like ILC from the bone marrow in
later life (11–13). Although some helper-like ILC express homing
receptors for certain tissues these cells are mainly thought to
proliferate on site under proinflammatory conditions (7, 14).
Given their localization at barrier surfaces ILC perfectly serve as
sensors for danger signals but also allergens and subsequently
mount early immune responses by rapid cytokine production.
They can act as initiators of the adaptive immune response by
crosstalk with dendritic cells and T cells finally shaping full blown
type 1, 2, or 3 immune responses [reviewed in (15)]. This review
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highlights the pathogenic role of ILC in the allergic skin diseases
with a main focus on ILC2.
ILC CLASSIFICATION AND PLASTICITY
NK Cells and ILC1
NK cells are considered the innate counterpart of memory
CD8+ T cells. They share similar functions such as cytotoxicity
and interferon-γ (IFN-γ) production and both express the
transcription factors Eomes and T-bet. ILC1 on the other hand
closely resemble TH1 cells. Both express and depend on T-
bet but lack EOMES and produce IFN-γ (16–19). NK cells
and ILC1 are involved in protecting the organism against
pathogens, viruses and tumors (16, 20, 21). Intraepithelial ILC1
can be found in Crohn’s disease patients and contribute as a
proinflammatory IFN-γ-producing population in an anti-CD40-
induced colitis model in mice (22). NK cells are suggested to
be important in enhancing inflammatory responses in a hapten
based contact hypersensitivity mouse model and human allergic
contact dermatitis (23, 24). Taken together these cell types are
mainly involved in mounting a type 1 immune response.
ILC2
ILC2, like TH2 cells, highly express the transcription factor
GATA3 and produce type 2 cytokines including interleukin-
5 (IL-5), IL-13 and the epidermal-growth-factor-like molecule
amphiregulin (7). ILC2 mediate pathology in a mouse model
of atopic dermatitis and promote wound healing in an IL-33-
dependent manner (25, 26). ILC2 promote type 2 driven immune
responses by promoting TH2 differentiation of naïve CD4
+ T
cells through production of IL-13, and by expression of MHC
class II on their cell surface induce T cell priming (27–29). In
addition, the inducible T-cell costimulatory (ICOS) molecule is
highly expressed on ILC2 regulating their activation status and
proliferation (30, 31). Moreover, activated ILC2 can express the
TNF receptor superfamily ligand OX40L, which promotes local
TH2 cell proliferation and adaptive type 2 inflammation (32).
Increased ILC2 numbers are linked to human allergic airway and
skin diseases like allergic asthma atopic dermatitis (25, 33–36).
Thus, type 2 immune responses are profoundly shaped by ILC2.
ILC3
ILC3 share RORγt expression with TH17 cells and can produce
IL-17 and IL-22 thereby helping the organism to fight against
bacteria and fungi and viruses, such as Citrobacter rodentium,
Salmonella enterica, Candida albicans, and rotavirus (2, 7, 37–
41). There are ILC3 expressing the chemokine receptor CCR6
which comprise lymphoid-tissue-inducer (LTi) cells and can
be CD4+ or CD4−. These cells are crucially important in the
embryonic development of many lymphoid organs, whereas in
adult mice they reside mainly in cryptopatches of the intestine
with low proliferation (42–45). In mice, CCR6− ILC3 can
express natural killer cell receptor such as NKp46 (NCR+ ILC3),
loose RORγt expression and upregulate T-bet, finally leading
to IFN-γ production (46–50). These “ex-RORγt+ ILC3” closely
resemble ILC1. A large population of ILC3 can be found in
the intestine where they are essential for maintaining barrier
integrity and immunologic tolerance to commensal bacteria of
the gut (51–53). IL-17 producing ILC3 are proposed to be
involved in plaque formation in a psoriasis mouse model based
on the topical application of the Toll-like receptor 7 (TLR7)
agonist imiquimod (54). Finally, elevated numbers of ILC3 are
found in blood and affected skin of psoriasis patients (55–57).
Given this data ILC3 are part of type 3 immune responses and
intestinal immunopathology.
ROLE OF ILC IN ATOPIC DERMATITIS
Impaired barrier function of the skin is a hallmark in
the pathogenesis of atopic dermatitis (AD). Loss-of-function-
mutations in the gene coding for the epidermal structure protein
filaggrin is strongly associated with an elevated risk to develop
atopic dermatitis by allowing elevated trans epidermal water
loss, higher prevalence of Staphylococcus aureus on the skin
and facilitated penetration of allergens (58–61). The type 2
inflammatory response in AD is known to involve innate and
adaptive immune cells like mast cells, eosinophils, and CD4+
TH2 cells, the latter producing type 2 cytokines like IL-4, IL-5,
and IL-13 (62). Since ILC2 are described in the skin (63) this
led to the hypothesis that innate lymphoid cells, especially ILC2,
may contribute to the pathogenesis of this frequently occurring
atopic disease (Figure 2).
ILC in Human Atopic Dermatitis
Significantly more ILC2 can be found in lesional skin biopsies
from patients suffering from atopic dermatitis in relation to
skin from healthy individuals (25, 36). These ILC2 produce high
amounts of the type 2 cytokines IL-5 and IL-13 and express the
membrane bound IL-33 receptor ST2 as well-receptors for IL-
25 and thymic stromal lymphopoietin (TSLP) (25, 36). These
changes are even more profound when ILC2 are isolated from
skin of house dust mite (HDM) allergic individuals that have
been challenged epicutaneously with HDM extract. IL-33 is able
to strongly enhance the expression of IL-13 and IL-5 and to
increase the migratory capacity of isolated skin-derived ILC2 in
vitro (36). Interestingly, ILC2 from atopic patients also express
higher amounts of the killer cell lectin-like receptor G1 (KLRG1),
which is even further elevated after stimulation with IL-33 or
TSLP (36).
Human ILC2 express the prostaglandin D2 (PGD2) receptor
chemoattractant receptor-homologous molecule expressed on
TH2 cells (CRTH2) (64, 65). PGD2 which is mainly produced by
mast cells induces ILC2migration, production of type 2 cytokines
and upregulation of the expression of IL-33 and IL-25 receptor
subunits (ST2 and IL-17RA) in vitro (66). The effects of PGD2 on
ILC2 can be mimicked by the supernatant from activated human
mast cells (through IgE-mediated degranulation) and inhibited
by a CRTH2 antagonist highlighting a cross-talk between mast
cells and ILC2 (66).
ILC2 respond to further mast cell mediators like cysteinyl
leukotrienes, particularly LTE4 (67). Human ILC express the
functional leukotriene receptors CysLT1 and its expression
is increased in patients with atopic dermatitis (67). LTE4
not only induces migration, promotes cytokine productions
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FIGURE 2 | Suggested pathogenic role of ILC2 in atopic dermatitis. (A) Loss-of-function-mutations in the gene coding for the epidermal structure protein filaggrin
allow elevated transepidermal water loss (TEWL), higher prevalence of Staphylococcus aureus (Staph Aureus) on the skin and facilitated penetration of allergens, e.g.,
from house dust mite (HDM). (B) Damaged keratinocytes (KC) release cytokines like interleukin-33 (IL-33), IL-25, and thymic stromal lymphopoietin (TSLP) which
activate dermal ILC2. (C) Activated ILC2 produce high amounts of IL-13 which stimulates epidermal Langerhans cells (LC). LC migrate to regional lymph nodes to
prime naïve T cells by antigen presentation via MHCII to promote development of TH2 cells that produce type II cytokines like IL-4, IL-5, and IL-13. (D) ILC2 can act as
antigen presenting cells for TH2 effector cells through antigen presentation via MHCII and/or CD1a prompting them to produce IL-2 which in turn sustains ILC2
activation and survival. (E) ILC2 can be activated by mast cell (Mast) derived prostaglandin D2 (PGD2) and cysteinyl leukotrienes LTE4. ILC2 in turn produce IL-5 which
promotes eosinophil (Eos) activation. Administration of montelukast can block LTE4-mediated activation of ILC2. IL-5 function can be therapeutically blocked by
specific monoclonal antibodies like mepolizumab. MHCII, major histocompatibility complex II; TCR, T cell receptor.
and upregulation of IL-33/IL-25 receptors in human ILC2
in vitro, but also enhances the pro-inflammatory effect of
the epithelial cytokines IL-25, IL-33, TSLP, and of PGD2
as seen by increased production of IL-5 and IL-13. This
effect of LTE4 can be partially inhibited by adding the
leukotriene antagonist montelukast. Finally, addition of IL-2
to LTE4 and epithelial cytokines significantly further amplifies
the activation of ILC2 (67). These findings clearly suggest a
pathogenic role of ILC2 in the pathogenesis if atopic dermatitis
in humans (Figure 2).
ILC in Atopic Dermatitis Mouse Models
Topical application of a synthetic form of active vitamin D3
(MC903) to the skin of mice can mimic atopic dermatitis-
like inflammation with a type 2 signature (68). Using the
MC903 AD mouse model Salimi et al. and Kim et al.
investigated inflammatory responses in the presence and absence
of ILC2. When ILC2 are depleted in Rag1−/− mice by
administering an anti-CD90.2 and/or anti-CD25 monoclonal
antibody this leads to an dramatically decreased ear swelling
response (25, 36). Furthermore, using Rorαsg/sg (Rorα-knockout)
bone marrow chimeric mice which lack ILC2, a markedly
reduced inflammatory response in the skin can be seen,
highlighting ILC2 as a main proinflammatory cell in this type
2 inflammatory model (36). An increase in IL-33 and IL-
25 expression has been reported in lesional skin of patients
with AD compared with healthy individuals underlining an
important role for these cytokines as proinflammatory ILC2
activating cytokines in AD (36, 69, 70). Strikingly, when
flow cytometry assisted cell sorting (FACS)-purified ILC2
from MC903-treated C57BL/6 wild-type mice are adoptively
transferred by intradermal injection into naïve C57BL/6 wild-
type recipient mice, the recipient mice develop AD-like skin
reactions with a type 2 T cell response indicating that these
innate cells alone are capable of eliciting an AD-like skin
response (25).
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FIGURE 3 | Context dependent role of ILC2 in type 1 and type 2 dominated contact hypersensitivity. Contact allergens irritate and penetrate the upper skin layers. (A)
Typical contact allergens like TNCB or oxazololone cause ROS and ATP release from damaged keratinocytes (KC) and uptake by epidermal Langerhans cells (LC).
(B,C) LC migrate to skin draining lymph nodes and promote a type 1 driven immune response mediated by TH1 and NK cells resulting in increased IFN-γ and IL-2
production. (D) Higher availability of IL-2 for NK cells results in their enhanced activation and effector cytokine production (IFN-γ, granzyme, perforin). (E) ILC2 are
likely to suppress LC migration, TH1 polarization and NK cells activation in this type 1 CHS response via mechanisms that are currently not well-understood. (F)
Protein allergens like papain or haptens like FITC cause IL-33 release from keratinocytes (KC) which in turn activates dermal ILC2 to produce large amounts of IL-13.
(G,H) ILC2 derived IL-13 promotes trafficking of Langerhans cells (LC) to regional lymph nodes where they prime naïve T cells by interaction of MHCII/peptide/hapten
complex and T cell receptor promoting the development of TH2 cells and a type 2 biased immune response. (I) ILC2 can act as antigen presenting cells for TH2
effector cells prompting them to produce IL-2 which in turn sustains ILC2 activation and survival. (J) ILC2 compete with other innate effector cells like NK cells for the
survival factor IL-2 leading to a reduced/moderate NK cell activation. FITC, Fluorescein isothiocyanate; MHCII, major histocompatibility complex II; ROS, reactive
oxygen species; TCR, T cell receptor; NK, natural killer cell; ATP, Adenosine triphosphate.
Another possible mouse model to study eczema like
skin reactions are the “flaky tail” mice. These mice bear
a frameshift mutation in the murine filaggrin gene (flg)
resulting in expression of a truncated profilaggrin (∼215
kDa) instead of the normal high-molecular-weight profilaggrin
(>500 kDa) (71). Topical application of allergen to mice
homozygous for this mutation results in cutaneous inflammatory
infiltrates and enhanced cutaneous allergen priming with
increased development of allergen-specific antibody responses
(71). Saunders et al. characterized changes of ILC2 numbers
and their cytokine production in flg-mutant mice (72). These
mice show spontaneous atopic dermatitis-like inflammation
and develop compromised pulmonary function. In the skin
and skin draining lymph nodes of these mice, there is a
significant increase in the frequency of IL-5-producing ILC
compared to wild type animals. However, no differences in
cell numbers are seen for ILC1 and 3. Furthermore, flg-
mutant mice show higher skin infiltrates of eosinophils, mast
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cells and basophils (72). Even more astonishing, when flg-
mutant mice are crossed with Rag1−/− mice (Flgft/ftRag1−/−)
skin lesions but not lung inflammation occur as shown by
cutaneous expansion of IL-5-producing ILC2, indicating that
skin inflammation can develop independently of the adaptive
immune system in these mice (72). Regulation of ILC responses
by adaptive immune cells is also reported in other tissues (73).
Finally, increased frequency of ILC2 can be found in skin blisters
taken from non-lesional skin of patients with filagrin mutations
compared with the skin of filagrin wildtype subjects (72). Taken
together, loss of filagrin function in humans and mice is clearly
linked to increased ILC2 activation and disease progression in
atopic dermatitis.
This latter model, however, has been challenged recently by
the work of Schwartz et al. which provides evidence that atopic
dermatitis like lesions can evolve independent of ILC2 and ILC2-
derived cytokines in Filaggrin-mutant (Flgft/ft) mice bred on
an ILC2-deficient background (74). Interestingly, inflammation
in these mice following MC903 treatment requires IL-1β and
IL-1R1-signaling but is independent of NOD-, LRR- and pyrin
domain-containing protein 3 (NLRP3) inflammasome activation
and results in elevated numbers of IL-1β-responsive connective
tissue mast cells (74). Finally, Flgft/ft mice do not develop skin
inflammation under germ-free compared to SPF conditions
indicting a crucial role for the microbiome in promoting
proinflammatory immune responses in this mouse model (74).
This issue will be discussed in more detail in a later section.
ILC2 as Possible Therapeutic Targets in AD
Development of ILC2 depends on the transcription factor
receptor-related orphan receptors alpha (RORα) and lack of
RORα results in impaired lung inflammation in response to
protease allergen in mice despite normal TH2 cell responses (75).
Dai et al. provide evidence that a synthetic RORα/γ inverse
agonist (SR1001) is able to suppress inflammation in the MC903-
induced atopic dermatitis mouse models. Topical treatment with
SR1001 reduces epidermal and dermal inflammation, suppresses
the production of type 2 cytokines and TSLP, and reverses
impaired keratinocyte differentiation (76). Since SR1001 also
inhibits RORγ signaling it is quite possible that RORγt+ ILC3
functions may also be impaired (42). If topical inverse agonists
for RORα may have anti-inflammatory functions in humans
remains to be elucidated.
A crucial role for the IL-33/ILC2 axis in the pathogenesis
of AD has been proposed by Imai et al. The authors
generated a transgenic mouse line which overexpresses IL-
33 in keratinocytes. These mice spontaneously develop an
itchy dermatitis closely resembling AD at age 6–8 weeks
with thickened epidermis, skin infiltration of eosinophils and
mast cells, and high histamine and IgE levels in the blood
(77). Moreover, IL-5 and IL-13 expressing ILC2 numbers
are significantly increased in lesional skin, peripheral blood,
and regional lymph nodes. Administering a neutralizing
monoclonal anti-IL-5 antibody results in a marked reduction
of the inflammatory response as shown by a decreased
peripheral blood eosinophil count, milder thickened epidermis
and lower inflammatory infiltrates including eosinophils (77).
Unfortunately, a randomized, placebo-controlled parallel group
design study in patients with AD could not detect a clinical
improvement by administering a monoclonal antibody to human
interleukin-5 (mepolizumab) in two single doses of 750mg, given
1 week apart, despite a significant decrease in peripheral blood
eosinophils (78).
ROLE OF ILC IN ALLERGIC CONTACT
DERMATITIS
Allergic contact dermatitis (ACD) is a prevalent inflammatory
skin disease triggered by low molecular weight organic chemicals
or metal ions which penetrate the skin and bind covalently
or by complex formation to proteins thereby activating the
innate and adaptive immune response. ACD can be separated
into two phases. The sensitization phase, were antigen upon
first encounter with the skin is taken up by dendritic cells
and transferred to the regional draining lymph nodes to
be presented to antigen specific T-cells for priming. And
the elicitation phase that is induced by subsequent antigen
contact and leads to an infiltration of antigen-specific T-cells
into the skin peaking 24–48 h after second antigen contact.
In the mouse model of ACD, the contact hypersensitivity
(CHS) model, hapten-specific CD8+ cytotoxic T-cells are
thought to be the key effector cells in the elicitation phase
rendering CHS a classical type 1 driven adaptive immune
response (Figure 3). Typical haptens used in these models
comprise oxazolone, 2,4,6-Trinitrochlorobenzene (TNCB) or
2,4-dinitrofluorobenzene (DNFB) (79–81). In addition, we and
others have previously demonstrated that sensing of danger
signals by cells of the innate immune system including dendritic
cells, neutrophils, and mast cells represent a crucial element in
the initiation and elicitation of CHS responses (82–86).
NK Cells in Type 1 Dominated CHS
Responses
Group 1 ILCs consisting of NK cells and ILC1 are involved in
inflammatory bowel and allergic skin diseases in mice (12, 24,
87, 88). Regarding ACD Carbone et al. were able to characterize
CD56highCD16−CD62L− NK cells in an ex vivo human model
which accumulate in affected skin of hapten allergic human
individuals and these NK cells release type 1 cytokines and
induce keratinocyte apoptosis in vitro (23). In mice NK cells can
be further subdivided into two distinct subsets: CD49a+DX5−
liver-resident (Trail+) and CD49a−DX5+ conventional NK cells
(cNK) (12). Furthermore, cNK cells seem to express much higher
amounts of the transcription factor EOMES (87). Liver-resident
NK cells can mediate long-lived, antigen-specific adaptive recall
responses to haptens like DNFB and oxazolone independent
of B cells and T cells (24). Preceding was the finding that a
CHS response to several haptens can be elicited in Rag2−/−
mice lacking T- and B-cells but not in mice that either contain
dysfunctional NK cells (SCID × beige mice) or completely lack
NK cells (Rag2−/− Il2rg−/− mice). A proper CHS response
can be transferred by FACS-purified antigen-specific Thy-1+
Ly49C-I+ liver-resident NK cells from sensitized Rag2−/− mice
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when transferred into naive Rag2−/− Il2rg−/− recipients (24).
The same NK cell type seems to mount antigen specific
immunity against certain viral pathogens as well (88). Our
own investigations using the hapten TNCB support the role of
EOMES+ cNK cells as the dominant proinflammatory innate
cell type in the early phase of contact hypersensitivity. NK
cell numbers increase significantly 24 h in the ear skin of mice
after allergen challenge and produce type 1 marker cytokines
like IFN-γ and TNF (89). Taken together, NK cells seem to
represent a major driving force of the innate immune system in
CHS pathogenesis pathogenesis (Figures 3A–D).
Helper-Like ILC in Type 1 Dominated CHS
Responses
Very little is known about the involvement of helper-like ILC in
the pathogenesis of CHS, however there has been some indirect
evidence for it in the past. ILC2 are known to be a major source
of IL-13 production thus playing a crucial role in innate type
2 immune responses to worms and inhaled allergens (90, 91).
IL-13-deficient mice (Il13−/−) show impaired TH2 responses
induced by epicutaneous ovalbumin (OVA) exposure whereas
i.p. sensitization is normal and results in responses equivalent
to wild type mice (92). Interestingly, Il13−/− mice display an
even enhanced ear swelling responses to the hapten DNFB,
which is also known to elicit a type 1 T-cell driven immune
response (93), compared to wild type mice. At the time, this
finding was interpreted as a lack of TH2-mediated suppression
but it’s tempting to speculate that impaired ILC2 function in
this mouse model may also have contributed to a disinhibited
and thus exaggerated type 1 immune response. We recently
characterized cell numbers and cytokine production of all ILC
subgroups (ILC1-3 and NK cells) during the elicitation phase
of a CHS mouse model based on the hapten TNCB using an
ILC reporter system (89). Numbers of ILC are elevated in skin
draining lymph nodes, show an activated phenotype and produce
elevated amounts of their marker cytokines IL-13 and IL-5 at
late time points (48 and 72 h), i.e., during the resolution phase
of the inflammatory response in the skin. On the other hand,
NK cell numbers and their production of IFN-γ and TNF are
highest 24 h after allergen challenge paralleling the strongest skin
inflammation period (89). The latter is expected since TNCB
is known to elicit a type 1 driven immune response (93, 94).
However, lack of ILC achieved by either antibody mediated
depletion using an anti CD90.2mAb in Rag1−/−mice or by using
mice that selectively lack ILC2 [Rorαsg/floxIl7rCre/+mice (29)]
results in a significantly enhanced and long lasting inflammatory
response (89). The ear infiltrate of ILC depleted mice show
a tendency toward a more type 1 biased immune response
indicated by increased numbers of T-bet+ CD4+ T-cells (89).
This data supports the concept of a counter regulatory role for
ILC2 in CHS (Figures 3A–D).
Helper-Like ILC in Type 2 Dominated
Allergic Skin Responses
Some allergens like Fluorescein isothiocyanate (FITC) and
papain rather induce allergic type 2 immune responses with
increased IL-4 producing TH2 cell infiltrates in murine skin when
reapplied topically or intradermally (28, 95, 96), suggesting that
ILC2 might rather play a proinflammatory role in these models.
Along this line we demonstrated in a papain skin challenge
model that lack of IL-13-producing ILC2 leads to a marked
reduction of inflammation with less skin infiltrating TH2 cells
[(28); (Figures 3F–J)]. A first therapeutic approach in type 2
dominated allergic skin responses has been proposed by Bao
et al. They demonstrate that ILC2 numbers are increased in
the skin of FITC-challenged mice. In addition, intraperitoneal
injection of the cycloartane triterpene saponin Astragaloside
IV during the sensitization phase leads to a reduction of the
inflammatory response as seen by a decreased ear swelling
response, less production of pro-allergic cytokines like IL-
33 and TSLP, and significantly reduced numbers of ILC2
in the skin of these mice (97). Thus, ILC2 seem to have
contrary roles in type 1 and type 2 dominated allergic skin
reactions, respectively (Figure 3).
ROLE OF DERMAL ILC2 IN INNATE AND
ADAPTIVE IMMUNE CROSS TALK
Antigen Presentation by MHCII
ILC2 and ILC3 express MHCII molecules on their surface and
can act as antigen presenting cells for helper T cells (29, 51, 52).
Our own analysis of MHCII expression on ILC2 revealed that in
skin draining lymph nodes of mice ∼50% of the ILC2 express
MHCII, while in the skin only ∼3% express MHCII. Antibody
mediated depletion of ILC leads to a significant reduction of
MHCII positive ILC2 both in skin and LN (89). Currently, we
can only speculate that ILC2 might regulate effector T cells
in a direct fashion via MHCII. In line with this, Oliphant
et al. recently demonstrated that MHCII expression on ILC2
and subsequent antigen presentation to CD4+ T cells is crucial
for successful helminth expulsion in mice (29). The crosstalk
between ILC2 and CD4+ T cells seems to involve IL-2 since
activated CD4+ T cell-derived IL-2 has been shown to synergize
with IL-33 to stimulate ILC2 (29). Thus, lack of ILC2 may
lead to a higher availability of IL-2 for proliferation of other
effector cells like NK cells leading to an augmented response
in CHS.
Antigen Presentation by CD1a
Another way how ILC2 might crosslink innate and adaptive
immunity is by expressing the lipid-presenting molecule CD1a.
Other than classical MHC proteins that present peptides, CD1
molecules present endogenous and exogenous lipid antigens
to T lymphocytes (98). In a CHS model using the poison
ivy-derived lipid contact allergen urushiol, CD1a expressing
Langerhans cells are important to promote CD1a-restricted
CD4+ T cells to produce IL-17 and IL-22. Furthermore,
treatment with blocking antibodies against CD1a alleviates skin
inflammation dramatically (99). More recently Hardman et al.
demonstrated in a human skin challenge model that skin-derived
ILC2 not only express CD1a but are also capable of helping
CD1a-reactive T cells to sense S. aureus components in an
cytosolic phospholipase A2 (PLA2G4A) and TLR-dependent–
dependent manner, suggesting a new role for ILC2 in lipid
surveillance of the skin (100). Currently, it is unclear whether
this also applies for the adaptive immune response against
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urushiol. Taken together CD1a expression on ILC2 seems to
be clearly involved in shaping the phenotype of adaptive T
cell responses.
Crosstalk With Basophils and
Macrophages
Mashiko et al. reported significantly elevated frequencies
of basophils, ILC and TH2 cells in the lesional skin of
AD patients compared to patients suffering from psoriasis.
Interestingly, basophils and ILC2 are positively correlated in
skin, whereas skin basophils are inversely correlated with blood
ILC2 suggesting that skin basophils may attract circulating
ILC2 to skin of AD patients by IL-4 production (101). Kim
et al. detected elevated numbers of basophils and ILC that
form clusters in inflamed human AD skin compared to
control skin. Using the MC903-based AD mouse model in IL-
4/GFP reporter mice, they demonstrated that murine basophil
responses preceded ILC2 responses and those basophils are
the dominant IL-4-producing cell type in inflamed skin. In
addition, ILC2 express the IL-4 receptor IL-4Rα and proliferate
in an IL-4-dependent manner. Finally using Il4−/− mice Kim
et al. provide evidence that especially basophil-derived IL-
4 is necessary for proinflammatory ILC2 responses in the
skin (102).
Most notably, Egawa et al. have shown that basophil-derived
IL-4 converts Ly6C+CCR2+ inflammatory monocytes into anti-
inflammatory M2 macrophages in an IgE-mediated chronic
allergic inflammation (IgE-CAI) mouse model, a model where
basophils rather than mast cells and T cells play a critical
role for the elicitation of allergic response (103, 104). In this
model, skin infiltrating monocytes acquire anM2-like phenotype
in an IL-4R- and basophil-dependent manner and adoptive
transfer of Ly6C+CCR2+ inflammatory monocytes dampens
the exacerbated IgE-CAI in CCR2−/− mice which also requires
IL-4R signaling (103). Thus, it is tempting to speculate, that
basophil-derived IL-4 may promote pro-inflammatory responses
via ILC2 and anti-inflammatory signals via M2 macrophages at
the same time, leading to a counterbalanced immune response.
However, the role of ILC2 in the IgE-CAI model is not known
so far.
On the other side, ILC2 have been shown to promote
polarization of the anti-inflammatory M2 macrophages by
producing type-2 cytokines (IL-4, IL-5, and IL-13) in an renal
ischemia-reperfusion injury model and experimental cerebral
malaria (105, 106). Furthermore, in obese mice PD-1high ILC2
are inhibited by PD-L1 expressing M1 macrophages which is
promoted by TNF. PD-1 blockade improves ILC2 function,
reinforces type 2 innate responses and promotes adipose
tissue homeostasis (107, 108). Interestingly, in an serum-
induced arthritis mouse model ILC2 were indispensable for
dampening proinflammatory IL-1β secretion by bone marrow-
derived macrophages (109). Finally, basophil-derived IL-4 seems
to be essential for M2 macrophage mediated trapping of
Nippostrongylus Brasiliensis larvae in the skin during second
infection of mice thereby leading to reduced worm burden in the
lung (110). However, basophils had no apparent contribution to
worm expulsion from the intestine highlighting their crucial role
in the skin (110).
Taken together, there seems to be an intense crosstalk between
basophils, ILC2 and macrophages involving cytokines like IL-
4, IL-13, and IL1β and resulting in differential polarization of
macrophages dependent on the disease model. How these three
cell type interact in AD and CHS remains to be elucidated.
Crosstalk With Dendritic Cells
Using the protease-allergen papain which induces type 2 allergic
airway and skin inflammation we showed that ILC2 are
necessary for mounting an appropriate antigen specific TH2
memory response and that ILC2 activation clearly precedes TH2
involvement in papain induced airway and skin inflammation
(28). Furthermore, ILC2-derived IL-13 is needed for the
activation and expansion of an allergen-induced subset of
dendritic cells (CD11b+CD103−IRF4+) which produce the TH2
cell chemoattractant CCL17. Using ILC2-deficient mice, we
demonstrated that dermal ILC2 are crucial to mediate expansion
of CCL17+ dendritic cells after skin challenge with papain
finally leading to an effective TH2 memory response. Thus, ILC2
licensing of dendritic cells is a critical component of the memory
TH2 cell response to certain allergens at barrier sites (28).
INFLUENCE OF SKIN MICROBIOTA ON
ILC2 IMMUNITY
As mentioned earlier, filaggrin mutant mice significantly differ in
their microbiome composition compared to wild type mice and
do not develop skin inflammation under germ-free conditions
prompting a crucial role for the microbiome in shaping this
setting (74). Several studies have investigated the role of skin
commensal bacteria in shaping the host immune cell functions of
this organ (111–113). This mostly involves skin derived dendritic
cells as sensors of bacterial antigens which promote development
of commensal-specific T cells. These T cells help to improve
tissue repair and protection to pathogens rendering them as
important players in the skin homeostasis (111, 112).
When analyzing different skin-derived bacterial strains in a
pediatric AD cohort over time, Byrd et al. were able to detect
certain clonal S. aureus strains which are associated with more
severe disease (113). Interestingly, heterogeneous Staphylococcus
epidermidis strains were found in patients with less severe disease
indicating that clonal expansion of certain bacterial strains can
trigger proinflammatory responses in human AD. Furthermore,
S. aureus isolates from AD patients with more severe flares can
induce epidermal thickening and expansion of cutaneous TH2
and TH17 cells in a murine AD model (113).
These findings are suggesting a role of the microbiome to
shape ILC2 functions as well. Interestingly, ILC2 distribution
and homeostatic function in bone marrow, fat, lung, gut,
and skin seems to be independent of commensal microbiota
when comparing SPF to germ free mice (114). However, in
mouse model of chronic obstructive pulmonary disease (COPD),
challenge with S. aureus or Haemophilis influenzae lead to loss
of GATA-3 expression in ILC2 and a subsequent increase in the
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expression of IL-12Rβ2, IL-18Rα, and T-bet giving them an ILC1-
like phenotype (115). This ILC2 plasticity can also be influenced
by viral stimuli especially influenza A virus (115).
Taken together, there is substantial evidence that
the microbiome is involved in shaping ILC2 function
and plasticity, especially in inflammatory lung diseases.
Whether this concept also applies to the pathogenesis of
inflammatory skin disease like AD and CHS remains to
be determined.
TYPE 1 AND TYPE 2 COUNTER
REGULATION IN CHS
Type 1 and type 2 immune responses are known to tightly
counter-regulate each other (116). TH1 cytokines such as IFN-
γ have been shown to antagonize the function of ILC2 and
type 2 innate immune responses in mouse models of allergic
lung inflammation and viral respiratory tract infections (13,
117). ILC2-mediated lung inflammation is enhanced in the
absence of the IFN-γ receptor on ILC2 cells in vivo and IFN-γ
effectively suppresses the function of tissue-resident ILC2 cells,
two observations that clearly suggest a suppressive function of
type 1 cytokines on ILC2 (13). Our own investigations reveal
that TNCB based CHS in a mouse model is counter regulated
by activated ILC, since lack of all ILC or ILC2 alone leads to
a dramatic increase in the inflammatory response with a type 1
immune response bias (89). More recently, it has been reported
that in the early stage of papain-induced lung inflammation in
mice, depletion of NK cells results in increased numbers and
cytokine production of ILC2, suggesting that NK cells negatively
regulate ILC2 (118). Hapten based CHS experiments in Il15−/−
mice, which lack NK cells, demonstrate dramatically reduced
ear swelling responses and at the same time increased numbers
of ILC2 in skin and skin draining lymph nodes (89). Thus, a
mutual balance between type 1 and type 2 immunity may also
exist in CHS, in whichNK cells negatively regulate ILC2 and ILC2
counter regulate type 1 immune responses mainly driven by NK
cells, TH1, and TC1 cells.
Recently, Kim et al. identified IL-10-producing lineage
negative lymphoid cells that show elevated numbers in the
axillary as well as inguinal lymph nodes and ear tissues of
Oxazolone challenged mice suggesting a possible regulatory role
of ILC (119). These cells were designated “ILC10” and identified
by expression of markers like CD45, CD127, and Sca-1, while
detailed characterization of the exact ILC subpopulation was not
provided. Along the same line, an IL-10 producing ILC2 effector
cell population has recently been described in murine lung and
suggested to regulate immune responses in a papain induced
allergic lung inflammation model (4). These studies prompted
us to address the presence of IL-10 producing ILC. Using highly
sensitive IL-10 transcriptional reporter mice (120) we, however,
could not identify relevant numbers of IL-10 transcribing lineage
negative cells in different tissues (skin, lymph nodes, blood, and
spleen) in the TNCB induced CHS model (89). Thus, at least in
our hands ILC derived IL-10 does not appear to be responsible for
the regulatory effects of ILC in type 1 dominated CHS of the skin.
Nevertheless, ILC2 are reported to promote regulatory T
(Treg) cell expansion, thus framing the hypothesis that ILC2 can
regulate inflammation indirectly. Molofski et al. demonstrated
that ICOSL expression by ILC2 can stimulate ICOS+ Treg cells,
providing a potential indirect link between IL-33 and Treg
cells (121). In line with this, Rauber et al. could demonstrate
that IL-9 producing ILC2 are crucial in promoting Treg driven
anti-inflammatory effects in an antigen-induced arthritis mouse
model. This ILC2/Treg interaction was dependent on direct cell
contact involving ICOS–ICOSL interaction (122).
We recently showed that IL-33-induced OX40L expression
by ILC2 is critical for tissue-specific expansion of Treg
cells (32). Moreover, our data indicates that OX40L/OX40-
driven interactions between ILC2 and Treg cells preferentially
expands GATA3+ Treg cells, which are thought to be
tissue-resident and functionally primed (123). IL-33-induced
OX40L expression by ILC2 and the associated Treg cell
expansion seems to be restricted to specific anatomical locations
such as the airway and adipose tissue but not LN or gut
(32). Thus, it remains unknown if a similar mechanism or
alternative ILC2-independent suppressive pathways are involved
in the skin.
Malhotra et al. recently found skin resident RORα-expressing
Tregs to dampen ILC2-driven inflammation in a mouse
model for atopic dermatitis (124). This effect is thought
to be based on the enhanced expression of TNF ligand–
related molecule 1 (TL1A) and death receptor 3 (DR3)
on ILC2 as well as suppressed IL-4 expression. RORα-
expressing Tregs are found in higher numbers in human skin
compared to peripheral blood suggesting a possible counter
regulatory role for these cells in ILC2-driven allergic skin
diseases (124).
Taken together, these data show that ILC2 can act as
modulators of the adaptive immune response and that the
functional outcome very much depends on the context of the
inflammatory reaction that is analyzed. In type 2 dominated
skin inflammation ILC2 seem to be primarily proinflammatory
while in the context of a type 1 dominated immune response
ILC2 can act as regulators that help to counterbalance the
inflammatory reaction (Figure 3).
CONCLUDING REMARKS AND OUTLOOK
Innate lymphoid cells are increasingly emerging as important
effectors of the innate immune system finally shaping a
distinctive adaptive immune response. This includes on the
one side important physiological functions in promoting wound
healing, adipose tissue homeostasis, protection from pathogens
and dampening of certain inflammatory disorders via Treg
induction. On the other side, ILC2 have been shown to be
important proinflammatory players in diseases like allergic
asthma and atopic dermatitis. In the case of atopic dermatitis
ILC2 have been described to be the major proinflammatory ILC
subtype accountable for the production of marker cytokines like
IL-13 and IL-5, cross-talk with other innate cells like basophils
and dendritic cells, and finally promoting the development of
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TH2 cells. ILC2 will continue to be of high interest as possible
targets in AD therapy, especially concerning their potential to
produce high amounts of cytokines.
Immunologic reaction in allergic contact dermatitis can
differ depending on the type of hapten used. Haptens like
TNCB or oxazolone inducing type 1 responses clearly favor NK
cells and TH1 cells as the driving proinflammatory force. In
these models ILC2 may have counter regulatory functions as
our own investigations suggest. On the other side, in allergic
type 2 responses of the skin, induced by distinct haptens like
FITC or protein allergens like papain, ILC2 seem to have a
proinflammatory role. These observations clearly emphasize a
context dependent function of ILC2 which is determined by the
type of model analyzed (type 1 or type 2 dominated).
Additionally, ILC2 have recently been shown to be part of
a neuro-immune interface. ILC2 function can be influenced by
the neuropeptide neuromedin U (NMU) secreted by cholinergic
neurons in the mucosal tissue of the gut and lungs. This goes
in line with other studies showing that further neuroendocrine
factors like norepinephrine, vasoactive intestinal peptide (VIP),
calcitonin gene-related peptide (CGRP), and acetylcholine can
modify ILC2 function as well (125–131). Furthermore, challenge
of mouse skin with the poison ivy compound urushiol leads to an
increase in IL-33 expression which can act on small to medium-
sized dorsal root ganglion neurons that innervate the skin and
express the IL-33 receptor ST2 (132). Strikingly, targeting IL-
33 by either neutralizing antibodies or intrathecal application
of ST2 siRNA results in significantly reduced itching and
subsequently less scratching behavior in these mice, suggesting
a new therapeutic approach in poison ivy ACD (132). Since
pruritus is a hallmark symptom of ACD in humans and
mice which is mediated by certain sensory neurons (133) it
is tempting to speculate that this new identified “neuron-
ILC2 unit” may also be important in the pathogenesis of AD
and ACD. This hypothesis is further supported by studies
showing that type 2 cytokines like TSLP and IL-4 can enhance
itching (134, 135).
Taken together, the picture of ILC function in allergic skin
diseases is far from complete. Further investigations especially
on the mode of action of how ILC modify immune responses
in a context dependent fashion are needed to fill this gap
of knowledge.
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